AAA March 2014 – Page 2

No nerves for NeuroPhage as it raises $17m

NeuroPhage Pharmaceuticals, a US-based developer of medication for neurodegenerative diseases backed by Shire and Mérieux, has closed a $17m series D round and will use the funds to advance clinical tests of its lead candidate, NPT088. Ireland-based biopharmaceutical company Shire and Mérieux Développement, the healthcare investment unit of France-based bioresearch corporation Institut Mérieux, participated in… Continue reading No nerves for NeuroPhage as it raises $17m